Top 4 Mid-Cap Stocks In The Biotechnology Industry With The Highest EPS Growth Forecast For Next 5 Years

Below are the top mid-cap biotechnology stocks on the NYSE and the NASDAQ in terms of EPS growth forecast for the next five years. Alnylam Pharmaceuticals, Inc. ALNY earnings per share growth forecast for the next five years is 46.09 percent. Alnylam Pharmaceuticals' trailing-twelve-month revenue is $62.20 million. Dyax Corp. DYAX EPS growth forecast for the next five years is 30.70 percent. Dyax's trailing-twelve-month gross margin is 87.10 percent. Insys Therapeutics Inc INSY EPS growth forecast for the next five years is 28.00 percent. Insys Therapeutics' PEG ratio is 2.64. China Biologic Products Inc CBPO earnings per share growth forecast for the next five years is 25.41 percent. China Biologic Products' trailing-twelve-month ROE is 32.90 percent.